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ABSTRACT 1 
 2 
Objective: Prediction of response/non-response to antipsychotics is especially important 3 
in patients with behavioral and psychological symptoms of dementia (BPSD) in whom 4 
antipsychotic exposure increases risks of death. We aimed to examine whether 5 
presence/absence of early improvement of BPSD with antipsychotics is associated with 6 
subsequent response/non-response. 7 
Design: Post-hoc analysis of the Clinical Antipsychotic Trials in Intervention 8 
Effectiveness with Alzheimer’s Disease (CATIE-AD) study (2001-2004) (trial 9 
registration: NCT00015548).  10 
Setting: 45 sites in the United States. 11 
Participants: 245 subjects (olanzapine, n=90; quetiapine, n=81; risperidone, n=74) with 12 
a DSM-IV diagnosis of dementia of the Alzheimer’s type who presented with a score of 13 
1 or more in the Brief Psychiatric Rating Scale (BPRS) at baseline (Phase 1 of CATIE-14 
AD). 15 
Intervention: Subjects were randomly assigned to treatment with olanzapine, quetiapine, 16 
risperidone, or placebo in a double-blind manner.  17 
  7 
Measurements: We examined associations between response at week 8, and 1 
demographic and clinical characteristics, including BPRS total score reduction at week 2, 2 
using logistic regression analyses. Prediction performance of binary classification 3 
(presence/absence) of improvement/no improvement at week 2 for response at week 8 4 
was examined. 5 
Results: BPRS total score reduction at week 2 (mean percentage score reduction, 12.6%) 6 
was significantly associated with response at week 8 (odds ratio, 1.18; 95% CI, 1.11-7 
1.26). The 5% score reduction cut-off at week 2 showed the highest accuracy (0.71) with 8 
sensitivity, specificity, PPV, and NPV of 0.76, 0.65, 0.69, and 0.72, respectively. 9 
Conclusion: Lack of even a very small early improvement with antipsychotic treatment 10 
may be a marker of subsequent non-response in BPSD.  11 
 12 
Keywords:  13 
antipsychotics, behavioral and psychological symptoms with dementia (BPSD), CATIE-14 
AD, dementia, prediction, response 15 
16 
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Introduction 1 
 2 
Behavioral and psychological symptoms such as delusions, hallucinations, agitation and 3 
aggression are difficult to manage in patients with dementia.1 While non-4 
psychopharmacological interventions are the first option to consider, drug treatments are 5 
widely used.2,3 Antipsychotic drugs have the best evidence for effectiveness in the 6 
management of behavioral and psychological symptoms with dementia (BPSD).4 7 
However, use of antipsychotic medication continues to be controversial and subject to 8 
scrutiny and international policy oversight, as substantial morbidity and increased 9 
mortality associated with their use5,6 led to a US Food and Drug Administration (FDA) 10 
black box warning against the use of atypical antipsychotics in patients with dementia.7,8 11 
More recently, a 2014 update to the American Psychiatric Association's Practice 12 
Guidelines recommends that antipsychotics must be used with caution and at the lowest 13 
effective dosage because they are associated with severe adverse events.9 Further, the 14 
frequency, severity and potential consequences of the adverse effects of antipsychotics 15 
are greater in older patients due to age-related changes in pharmacokinetic and 16 
  9 
pharmacodynamics parameters.10,11 Therefore, it would be clinically important to identify 1 
potential responders and non-responders to antipsychotic treatment as early as possible 2 
after treatment is initiated to inform benefit-risk considerations in individual patients.12,13 3 
If such response prediction is valid, those who are unlikely to respond to a particular drug 4 
could be switched to another treatment option, hence reducing exposure to antipsychotics 5 
that offer little clinical gain.12-14  6 
 7 
In patients with schizophrenia, a number of previous studies have shown that early 8 
improvement following antipsychotic drug use is associated with subsequent favorable 9 
treatment outcomes.12,13,15 Likewise, lack of early improvement with antipsychotics 10 
predicts unfavorable outcomes at endpoint and this has already been incorporated into 11 
treatment guidelines.16 The same holds for treatment of depression with 12 
antidepressants.14,17 However, no studies have investigated the ability of early symptom 13 
improvement to predict later response with antipsychotics in patients with BPSD.  14 
 15 
To investigate this, we conducted a post-hoc analysis of the data from the Clinical 16 
  10 
Antipsychotic Trial of Intervention Effectiveness-Alzheimer's disease (CATIE-AD)18,19 1 
to examine whether presence/absence of improvement with antipsychotics (olanzapine, 2 
quetiapine, and risperidone) after 2 weeks treatment would be associated with treatment 3 
response/non-response at week 8 in patients with BPSD.  4 
5 
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Methods 1 
 2 
Study design 3 
The CATIE-AD was funded by the National Institute of Mental Health to compare the 4 
effectiveness of antipsychotic drugs in patients with Alzheimer’s disease and psychosis 5 
or agitated/aggressive behavior. The study has been described in detail elsewhere.18,19 6 
Briefly, it was conducted between April 2001 and November 2004 at 45 clinical sites in 7 
the United States. Four hundred and twenty-one patients with a diagnosis of dementia of 8 
the Alzheimer’s type based on the Structured Clinical Interview of the Diagnostic and 9 
Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)20 or probable Alzheimer’s 10 
disease based on the National Institute of Neurological and Communicative Disorders 11 
Association (NINCDA-ADRDA),21 participated in the trial. Patients were initially 12 
randomized to olanzapine, quetiapine, risperidone, or placebo under double-blind 13 
conditions, and received treatment for up to 36 weeks or until treatment was discontinued 14 
for any reason (Phase 1). Medications were prepared in low-dose and high-dose capsules 15 
(olanzapine: 2.5 mg or 5.0 mg, quetiapine: 25 mg or 50 mg and risperidone: 0.5 mg or 16 
  12 
1.0 mg, respectively). Study physicians adjusted medication dosage based on their 1 
clinical judgment and patient response. 2 
 3 
Data used in this analysis were derived from the patients who were receiving olanzapine, 4 
quetiapine, or risperidone and received assessments with the Brief Psychiatric Rating 5 
Scale (BPRS)22 or the Neuropsychiatric Inventory (NPI)23 at both baseline and week 2 in 6 
Phase 1 of CATIE-AD. The protocols were approved by the local institutional review 7 
boards, and all patients gave written informed consent to participate in this trial. Ethical 8 
approval was not sought for this specific analysis that used completely anonymous data. 9 
 10 
Clinical Subtypes 11 
Based on the data in Phase 1 of CATIE-AD, patients were classified by age group (i.e. 12 
ages of ≤69 years or ≥70), sex, race (i.e. white vs. other), and dementia psychosis subtype 13 
(i.e. paranoid, misidentification, mixed, and non-psychotic). This categorization was 14 
based on factorial analysis of NPI delusions and hallucinations domains,24,25 which 15 
identified two factors: a ‘paranoid’ subtype (delusions of persecution and/or 16 
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abandonment); and a ‘misidentification’ subtype (misidentification phenomena and/or 1 
hallucinations). Patients who were experiencing both types of symptoms were described 2 
as ‘mixed’. 3 
 4 
Statistical analysis 5 
First, to examine factors associated with response at week 8, binary logistic regression 6 
analyses were conducted with antipsychotic medication used, gender, age group, race, 7 
dementia psychosis subtype (only for NPI analysis), total score in the BPRS or NPI at 8 
baseline, and reduction in the BPRS or NPI total scores from baseline to week 2. A 9 
multivariate model was used for the last 2 variables (i.e. total score in the BPRS or NPI 10 
at baseline, and reduction in the BPRS or NPI total scores from baseline to week 2) and 11 
univariate model for the other variables. With regard to the definition of response, a score 12 
reduction of ≥one minimal clinically important difference (MCID),26,27 defined as a half 13 
of the standard deviation (SD) of change from baseline at week 8 in the BPRS or NPI was 14 
adopted; MCIDs were 6.4 to 7.6 for BPRS and 8.3 to 10.5 for NPI, depending on the 15 
dataset generated with multiple imputations28 as described below.  16 
  14 
 1 
Next, the prediction performance of binary classification of early improvement at week 2 
2 (present or absent) for response at week 8 was examined. To this end, sensitivity, 3 
specificity, positive predictive value (PPV), and negative predictive value (NPV) of the 4 
consecutive cut-off points in 5% increments between 5% and 25% in the BPRS total or 5 
NPI total scores at week 2 were calculated. To seek the optimum cut-off point, accuracy, 6 
defined as (True Positive + True Negative) / Total N, was calculated. Accuracy depends 7 
on the number of observations, which may render it inferior to the careful and balanced 8 
consideration of sensitivity and specificity. To address this potential pitfall, cut-off points 9 
that demonstrated a level of ≥0.5 in both sensitivity and specificity with the highest degree 10 
of accuracy were examined.29 In addition, the area under the curve (AUC) of the receiver 11 
operating characteristic (ROC) was also calculated.  12 
 13 
Multiple imputation of the outcome and predictors was performed to deal with missing 14 
values, using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA.). To account for 15 
variability in imputed values, 100 imputed data sets were created using Proc MI (a 16 
  15 
procedure within SAS) using Markov chain Monte Carlo (MCMC) imputation method. 1 
Multiple imputation is a method in which missing values are replaced with predicted 2 
values from a regression model, but in order to reincorporate variance that is lost by using 3 
a simple prediction, a residual term is added to each value based on a normal distribution 4 
with mean zero and variance equal to the residual variance from the regression model. In 5 
the case of this study the imputation was single-chain done with 200 burn-in iterations, 6 
as are the default settings. The imputation was done 100 times (as mentioned above), the 7 
resulting datasets were then analyzed and the results were pooled using Proc 8 
MIANALYZE. Other statistical analyses, including additional available case analysis, 9 
were performed, using SPSS version 22.0 (IBM, New York). A p-value of <0.05 was 10 
considered statistically significant (two-tailed). 11 
12 
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Results 1 
 2 
Subject characteristics 3 
All two-hundred forty-five patients (olanzapine, n=90; quetiapine, n=81; risperidone, 4 
n=74) and 242 patients (olanzapine, n=90; quetiapine, n=80; risperidone, n=72) in the 5 
intention-to-treat (ITT) samples were included in the analyses for the BPRS and NPI, 6 
respectively. Demographic and clinical characteristics are summarized in Table 1.  7 
 8 
-------------------------------------- 9 
Insert Table 1 Here 10 
-------------------------------------- 11 
 12 
Factors associated with response to antipsychotic drugs at week 8 13 
The missing proportions (out of 245) for the variables included in the BPRS imputation 14 
model were 28.9%, 52.2%, and 62% respectively for the variable BPRS at weeks 4, 8, 15 
and 12. Baseline BPRS values and week 2 values were complete. The missing proportions 16 
  17 
(out of 242) for the variables included in the NPI imputation model were 28.1%, 51.6%, 1 
and 61.5% respectively for the variable NPI at weeks 4, 8, and 12. Baseline NPI values 2 
and week 2 values were complete. There were no missing values for other variables (i.e. 3 
age, sex, race, antipsychotics, or subtype). The total score reduction in the BPRS or NPI 4 
at week 2 was significantly associated with subsequent response to antipsychotic 5 
treatment at week 8 (Tables 2 and 3). In contrast, factors other than the total score in the 6 
BPRS or NPI at baseline failed to show any association with subsequent response. Results 7 
obtained with an available case analysis were similar to these findings (Supplementary 8 
Tables 1 and 2).  9 
-------------------------------------- 10 
Insert Tables 2 and 3 Here 11 
-------------------------------------- 12 
 13 
Prediction performance of presence/absence of improvement at week 2 for response at 14 
week 8 15 
  18 
The prediction performance of binary classification of early improvement at week 2 for 1 
response at week 8 is shown in Table 4; sensitivity and NPV were slightly higher than 2 
specificity and PPV. The 5% cut-offs in the BPRS and the NPI at week 2 showed the 3 
highest degree of accuracy for the prediction of response at week 8. The ROC analysis 4 
demonstrated high values for the use of BPRS and NPI total score reductions for the 5 
prediction of response at week 8 with 0.76 and 0.75, respectively. The 5% and 10% cut-6 
offs in BPRS and NPI at week 2 showed the highest degree of accuracy for the prediction 7 
of response at week 8, respectively, when available case analysis was employed 8 
(Supplementary Table 3).  9 
-------------------------------------- 10 
Insert Table 4 Here 11 
-------------------------------------- 12 
13 
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Discussion 1 
 2 
As the proportion of aging individuals within society increases, the management of BPSD 3 
represents an urgent unresolved clinical issue. To our knowledge, this is the first study to 4 
investigate the impact of presence/absence of early improvement with antipsychotic 5 
drugs on subsequent treatment outcomes in patients with BPSD. We found that the 6 
reduction in total score at week 2 was significantly associated with subsequent clinically 7 
important response at week 8 although the modest magnitude of the association should 8 
be taken into account. Furthermore, score reductions of 5% in the BPRS and NPI total 9 
scores at week 2 appeared to perform well as clinically relevant cut-offs, with the highest 10 
degree of accuracy for the prediction of response at week 8. Given the fact that NPVs 11 
were higher than PPVs, these findings suggest that, if there is no improvement in the early 12 
stage of treatment, continuation of the antipsychotic in question is likely to be futile.  13 
 14 
Previous studies focusing on patients with schizophrenia or major depressive disorders 15 
(MDD) have shown that presence/absence of early improvement with antipsychotics or 16 
  20 
antidepressants can be a robust predictor of subsequent response/non-response12,13,15,17,30-1 
32 although the conditions of psychosis and mood symptoms may substantially differ 2 
among patients with schizophrenia, MDD, and AD. In patients with schizophrenia, 3 
improvements such as a ≥25% reduction in the BPRS or a ≥20% reduction in the Positive 4 
and Negative Syndrome Scale (PANSS)33 total score at week 2 predict response at 4, 8, 5 
and 12 weeks, while lack of such initial improvement at week 2 is associated with poor 6 
outcomes thereafter.12,15,30 Such associations have also been previously identified in 7 
relation to antidepressant treatment.17,31,32 Since there has been no prior report of the 8 
degree of change that should be used to define early improvement with antipsychotic 9 
treatment in BPSD, we tested consecutive cut-off points to explore the optimum threshold. 10 
In contrast to those previous studies, optimally performing cut-offs were relatively low 11 
(5% for BPRS and NPI, respectively) in the current study. This discrepancy is likely 12 
attributable to differences in symptom trajectories over time in people with dementia 13 
compared to other illnesses and the heterogeneous nature of symptoms contained within 14 
the nonspecific treatment target that BPSD represents. In the present study, the mean 15 
percentage score reduction in the BPRS total score at week 2 was as low as 12.6% (from 16 
  21 
27.0 to 23.6), for which floor effects should be taken into account. This reduction is much 1 
lower than seen in schizophrenia trials. For example, one double-blind randomized 2 
controlled trial data of schizophrenia patients demonstrated that the mean percentage 3 
score reduction in the PANSS at week 2 was 29.2% (from 95.0 to 67.3) for risperidone 4 
and 21.1% (from 97.3 to 76.8) for quetiapine,34 which roughly corresponds to a 5 
percentage BPRS improvement of 30%.35 Thus, the symptom improvement from baseline 6 
to week 2 reported in schizophrenia seems greater than that in BPSD with modest severity. 7 
These low cut-off values (i.e. 5%), with high NPVs, seen in our study reinforce the 8 
observation that patients with no improvement at the early stage of antipsychotic 9 
treatment in BPSD are unlikely to derive any further clinical benefit thereafter. Prediction 10 
of non-response is especially important in patients with BPSD in whom the exposure to 11 
antipsychotic drugs has been reported to increase risks of serious side effects, including 12 
death.7,36 Those potential non-responders may benefit from a switch from antipsychotic 13 
treatment that will unlikely work to another treatment option at the earliest opportunity; 14 
this will also minimize the exposure to antipsychotic drugs and hence reduce such lethal 15 
adverse events.  16 
  22 
 1 
Prediction performance in the present study was high and comparable to that in previous 2 
studies that have included patients with schizophrenia; for example, lack of early 3 
improvement at 2 weeks predicted subsequent non-response at week 8 or 12 with NPVs 4 
of 0.73-0.84.12,15 Thus, early improvement with antipsychotic treatment could serve as a 5 
robust predictor of subsequent treatment response, irrespective of diagnoses. While the 6 
prediction performance in the present study seems high, it should be noted that 20-30% 7 
of the patients were still judged as false positives or false negatives. Therefore, further 8 
investigations are clearly needed to improve the prediction performance to reduce the risk 9 
of misclassifications.  10 
 11 
The association between lack of early improvement with antipsychotics and subsequent 12 
non-response could provide a clinically relevant opportunity to discontinue medications 13 
that carry significant risk of harm in people with dementia and explore alternative 14 
treatment options (where available) at an early stage. This is critically important since the 15 
  23 
use of antipsychotics can result in a variety of side effects,5 including increased 1 
mortality.5,7 Indeed, longer use of antipsychotics is associated with increased mortality5,7 2 
and there is also evidence that this association is dose-dependent.7 In the light of these 3 
findings, the use of antipsychotics is not recommended as a first-line treatment for 4 
BPSD.37 Despite these safety concerns, prescribing surveys have consistently shown the 5 
continuing and frequent use of antipsychotics for patients with severe BPSD, which 6 
clearly underscores the importance of the topic addressed by our study.38 On the other 7 
hand, while the results of this study suggest clinical utility of discontinuing the medication 8 
that does not seem to provide any further benefit and trying a next treatment option, there 9 
is not any better evidence-supported therapy, which is a dilemma in the treatment of 10 
BPSD.  11 
 12 
The results of our study must be interpreted in the light of some limitations. First, CATIE-13 
AD was not originally designed to examine whether presence/absence of early 14 
improvement with antipsychotics could predict subsequent treatment outcomes. The 15 
association between early improvement and subsequent response was derived from a 16 
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post-hoc analysis; therefore, appropriate caution is required in interpretation of the results. 1 
Second, only patients treated with olanzapine, quetiapine, or risperidone, were included, 2 
which limits any extrapolation of our findings to other antipsychotics. Third, the potential 3 
influence of medication dose was not taken into consideration since flexible dosing was 4 
employed in this study. Fourth, the choice of weeks 2 and 8 for the timing of assessments 5 
was based on previous studies that have examined prediction performance in patients with 6 
schizophrenia and MDD,15,17 but it may still be considered arbitrary. Fifth, other factors 7 
such as adverse events, which may work as predictors of poor subsequent response, were 8 
not taken into consideration in the present study since they were not evaluated in a 9 
systematic manner, using assessment scales. Further investigations focusing on the 10 
potential roles of adverse events in predicting subsequent outcomes are warranted. Sixth, 11 
the primary outcomes for this analysis were BPRS and NPI total scores. However, the 12 
total scores on these instruments include a broad range of symptoms and therefore may 13 
not always reflect treatment targets. Although we included dementia psychosis subtype 14 
as an independent variable in the logistic regression analysis for NPI and found no 15 
significant relationship in this regard, further investigations focusing on specific 16 
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symptoms are clearly needed. Seventh, although the odds ratios that predicted subsequent 1 
response were statistically significant, they were relatively small. Moreover, while 2 
accuracy of the prediction performance was found to be generally good, there still were 3 
many inaccuracies in the model. These results suggest that the response to antipsychotic 4 
treatment may not be easy to accurately predict solely based on early symptom 5 
improvement. In fact, treatment response has been reported to be associated with a 6 
number of factors, including genetic background.39 Further investigations such as genetic 7 
studies to identify more detailed predictors for good treatment response in BPSD are 8 
warranted. Thus, the results of this study should be interpreted with caution in the clinical 9 
settings. Finally, there was a large amount of missing data for the BPRS and NPI scores 10 
at week 8 (i.e. 52.2% and 51.6%, respectively), which we addressed through the use of 11 
multiple imputation. Although this method is a valid approach to missing data,40 and one 12 
which produced similar results for our main finding compared to available case analysis, 13 
we cannot be certain that the imputed data are completely representative of the original 14 
data. This is perhaps most relevant when considering the potential influence of 15 
medication dose and adverse events on drop-out and subsequent outcome. Furthermore, 16 
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since the CATIE design allowed participants to be transitioned to other treatments (i.e. 1 
switching from Phase 1 to Phase 2), clinical reasons for exit from Phase 1 were not 2 
randomly related with insufficient efficacy or adverse effects. Thus, those remaining in 3 
the study phase 1 may not be entirely representative of the group initially treated, which 4 
limits the generalizability of the findings in the present study. For these reasons, our 5 
observations should be viewed as preliminary and need to be confirmed in a prospective 6 
clinical trial.  7 
 8 
In conclusion, presence/absence of early improvement at week 2 with antipsychotic 9 
treatment may be a predictor of subsequent response or non-response at week 8 in the 10 
treatment of BPSD, as has been shown to be the case for depression and schizophrenia. 11 
This finding indicates that, especially in light of higher NPVs, evaluating patients early 12 
in the course of treatment with antipsychotic drugs help identify non-responders who are 13 
unlikely to benefit from continuation of the current antipsychotic. Although future 14 
prospective studies are needed to confirm those preliminary findings, the results of this 15 
study underscore the relevance of focusing on symptom trajectories in guiding 16 
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antipsychotic treatment on an individual basis to minimize unwanted adverse effects in 1 
the treatment of BPSD.   2 
 3 
4 
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